GH · Guardant Health, Inc.

131 filings

GH SEC Filings

Guardant Health, Inc. - 131 total filings

Filing record · 2018–202610-K810-Q248-K99

Showing 1–50 of 131 filings

Guardant Health, Inc. 8-K Report, Financial Results (Jul 30, 2026)

Guardant Health (GH) reported strong second quarter 2026 results, with total revenue of $335.0 million, up 44% year over year from $232.1 million. The growth was led by Oncology revenue of $219.1 million (up 38%, on approximately 63% higher test volume) and a sharp ramp in Screening revenue to $52.9 million from $14.8 million, driven by roughly 66,000 Shield tests versus 16,000 a year earlier. Biopharma & Data grew a more modest 9% to $60.9 million. Non-GAAP gross margin improved to 67% from 66%. Profitability remains negative and spending is rising. GAAP net loss widened to $120.1 million (from $99.9 million), and non-GAAP net loss was $56.2 million, roughly flat year over year. Non-GAAP operating expenses rose to $288.3 million from $215.3 million, reflecting commercial infrastructure and marketing investment behind Shield and Oncology. Free cash flow was $(69.5) million for the quarter. The company ended June 30, 2026 with about $1.2 billion in cash, cash equivalents, and restricted cash, though it carries roughly $1.5 billion in convertible senior notes. Management raised 2026 revenue guidance to $1.34–$1.36 billion (36%–38% growth, from $1.30–$1.32 billion). The raise is driven by Screening, now expected at $218–$230 million on 270,000–285,000 Shield tests. Guidance for non-GAAP operating expenses ($1.08–$1.10 billion) and free cash flow burn ($195–$205 million) was also increased, reflecting accelerated lab capacity investment. The company held its non-GAAP gross margin guidance at 64%–65%. Investors will likely focus on whether Shield's volume ramp and new coverage can keep pace with rising spending.

Jul 30, 2026 10-Q

Guardant Health, Inc. Quarterly Report for Q2 Ended Jun 30, 2026

Guardant Health, Inc. reported strong revenue growth of 44% year-over-year for the second quarter of 2026, reaching $335.0 million, and 46% for the first six months, totaling $636.6 million. This growth was primarily driven by a significant increase in test volumes across its oncology and, notably, its screening segment, with Shield screening test volume more than tripling. Despite this robust top-line performance, the company continued to incur substantial net losses, reporting $120.1 million for the quarter and $232.2 million for the first six months. These losses are a result of continued heavy investment in research and development, and a significant increase in sales and marketing expenses, up 59% and 60% for the respective periods, to support commercial expansion and product adoption. The company's balance sheet shows a healthy cash position of $1.2 billion as of June 30, 2026, providing ample liquidity for continued operations and investment. However, investors should note the ongoing legal proceedings, particularly the intellectual property dispute with TwinStrand Biosciences, which resulted in a significant jury verdict against Guardant Health, with a potential loss estimated between $0 and $250 million. While the company is contesting this verdict and has favorable developments in USPTO reviews of the patents, this remains a material contingent liability.

Jul 30, 2026 8-K

Guardant Health, Inc. 8-K Report, Shareholder Vote Results (Jun 18, 2026)

Guardant Health, Inc. (GH) held its Annual Meeting of Stockholders on June 17, 2026, with the results detailed in this 8-K filing. Key outcomes include the election of all director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company also sought advisory votes on executive compensation and the frequency of future advisory votes on executive compensation. While director elections and auditor ratification were strongly supported by shareholders, the advisory vote on executive compensation ("Say-on-Pay") did not receive majority approval. This indicates a potential disconnect between management's compensation practices and shareholder sentiment. Furthermore, shareholders voted overwhelmingly in favor of an annual advisory vote on executive compensation, suggesting a desire for more frequent engagement on this matter.

Jun 18, 2026 8-K

Guardant Health, Inc. 8-K Report, Financial Results (May 7, 2026)

Guardant Health reported first quarter 2026 revenue of $301.7 million, up 48% year over year from $203.5 million. Growth came mainly from Screening, where Shield revenue rose to $41.6 million from $5.7 million on about 44,000 tests versus 9,000 a year earlier. Oncology revenue grew 36% to $205.0 million on 47% higher test volume (about 86,000 tests), and Biopharma & Data grew 17% to $53.0 million. GAAP gross margin was 65% and non-GAAP gross margin was 66%, both up from the prior year. Profitability remains negative, though the non-GAAP picture is steadier. GAAP net loss widened to $112.1 million ($0.85 per share) from $95.2 million, driven by higher sales and marketing spending (up 62%) to build out Shield and oncology commercial infrastructure. Non-GAAP net loss narrowed to $58.7 million from $61.1 million, and adjusted EBITDA loss was roughly flat at $58.9 million. Free cash flow was negative $71.2 million, compared with negative $67.1 million a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled about $1.2 billion at March 31, 2026, against $1.5 billion of convertible senior notes on the balance sheet. The stockholders' deficit widened to $181.1 million from $99.3 million. Management raised 2026 revenue guidance to $1.30 to $1.32 billion (32% to 34% growth), up from $1.25 to $1.28 billion. Screening revenue guidance rose to $186 to $198 million on Shield volume of 230,000 to 245,000 tests, and oncology volume growth is now expected to exceed 35%. The company also raised its non-GAAP operating expense outlook to $1.05 to $1.07 billion, while keeping its free cash flow burn guidance at $185 to $195 million and its non-GAAP gross margin guidance at 64% to 65%. Investors will want to track whether Shield volume and reimbursement can keep scaling while operating expenses rise.

May 7, 2026 10-Q

Guardant Health, Inc. Quarterly Report for Q1 Ended Mar 31, 2026

Guardant Health, Inc. reported a significant increase in revenue for the first quarter of 2026, reaching $301.7 million, a 48% jump from the prior year's $203.5 million. This growth was primarily driven by a substantial increase in test volumes across its oncology and screening segments, with the Shield screening test showing remarkable 633% revenue growth. Despite strong top-line performance, the company continued to experience operating losses, with a net loss of $112.1 million for the quarter, compared to $95.2 million in the same period last year. This widening net loss reflects increased operating expenses, particularly in sales and marketing, which grew by 62% to support commercial expansion and marketing initiatives. The company maintains a solid liquidity position with approximately $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2026, which it believes is sufficient to fund operations for over 12 months.

May 7, 2026 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Apr 27, 2026)

Guardant Health, Inc. (GH) announced a significant change in its executive leadership with the resignation of its Chief Medical Officer, Craig Eagle, M.D., effective May 8, 2026. This departure marks the end of Dr. Eagle's tenure in a critical role overseeing the company's medical strategy and clinical development, particularly relevant given Guardant Health's focus on cancer diagnostics and precision medicine. Investors will be keen to understand the implications of this change on the company's ongoing research, clinical trial progress, and its overall medical vision moving forward. The company has not yet announced a successor for Dr. Eagle. The absence of immediate plans for a replacement could suggest a period of transition or a strategic review of the CMO role. Investors should closely monitor future filings and communications from Guardant Health for updates on leadership appointments and any potential shifts in the company's medical and scientific direction.

Apr 27, 2026 10-K

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2025

Guardant Health, Inc. (GH) has filed its 10-K for the fiscal year ending December 31, 2025. The company reported total revenue of $982.0 million, a significant increase of 33% from the prior year, driven by strong growth in both its Oncology and Biopharma & Data segments. Despite this revenue growth, Guardant Health continued to incur substantial net losses, reporting a net loss of $416.3 million for the year, which is an improvement from the $436.4 million net loss in 2024. The company's expansion of its sales and marketing efforts, particularly for its Shield blood test for colorectal cancer screening, contributed to increased operating expenses, with sales and marketing expenses rising 36% year-over-year. Guardant Health remains focused on its strategic objectives of expanding clinical utility, increasing reimbursement, and strengthening customer relationships across its product portfolio, which spans therapy selection, minimal residual disease detection, and early cancer screening. Financially, the company ended the year with a strong cash position of approximately $1.3 billion in cash, cash equivalents, and marketable debt securities, providing ample runway. Key developments include the FDA approval and commercial availability of the Shield blood test for colorectal cancer screening, and continued investment in R&D to expand its technology platform. However, the company continues to face significant risks related to its profitability, ongoing losses, reimbursement uncertainties from payers, competitive pressures, and potential regulatory changes.

Feb 19, 2026 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Feb 19, 2026)

Guardant Health (GH) reported strong fourth quarter and full year 2025 results, with total revenue of $281.3 million in Q4 (up 39% year-over-year) and $982.0 million for the full year (up 33%). Growth was led by Oncology, where test volume rose 38% in Q4 and 34% for the year, and by the rapid ramp of Shield, the company's blood-based colorectal cancer screening test, which generated $35.1 million in Q4 screening revenue from roughly 38,000 tests versus 6,400 a year earlier. Non-GAAP gross margin expanded to 66% for both the quarter and the full year, and free cash flow burn narrowed to $(233) million in 2025 from $(275) million in 2024. Net loss improved to $(416.3) million for the year from $(436.4) million, and non-GAAP net loss narrowed to $(228.1) million. Management guided 2026 total revenue to $1.25 to $1.28 billion, implying 27% to 30% growth. The outlook calls for Oncology revenue growth of 25% to 27% with approximately 30% volume growth, Biopharma & Data growth in the low double digits, and Screening revenue of $162 to $174 million on 210,000 to 225,000 tests. Non-GAAP gross margin is guided to 64% to 65%, non-GAAP operating expenses to $1.03 to $1.05 billion (up 14% to 16%), and free cash flow burn to $185 to $195 million, an improvement from 2025. The company ended 2025 with about $1.3 billion in cash, cash equivalents, restricted cash and marketable debt securities, after a November 2025 follow-on offering (net proceeds of $327.3 million) and $402.5 million of 0% convertible notes due 2033. Total convertible notes on the balance sheet rose to $1.5 billion, which is a point investors will want to track alongside the path to free cash flow breakeven. The release also highlights strategic progress: a Merck collaboration for companion diagnostics, first Guardant360 CDx companion diagnostic approval in colorectal cancer, expanded tissue-free Guardant Reveal monitoring, TRICARE coverage for Shield, early health system integrations, and the acquisition of MetaSight Diagnostics for $59.0 million upfront plus up to $90.0 million in contingent consideration. Note that the 2026 free cash flow guidance text refers to "2025" in its wording, which appears to be a typographical error for 2026.

Feb 19, 2026 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Jan 12, 2026)

Guardant Health (GH) furnished preliminary, unaudited results for Q4 and full year 2025 via an 8-K filed January 12, 2026, ahead of its J.P. Morgan Healthcare Conference presentation. Fourth-quarter revenue was approximately $280 million, up 39% year over year, driven by strong Oncology and Screening volume. Full-year 2025 revenue was approximately $981 million, up 33%, with growth accelerating through the year. Oncology tests reached roughly 276,000 for the year (up 34%), and Shield screening tests reached roughly 87,000, versus about 6,400 in Q4 2024, reflecting rapid adoption of the blood-based colorectal cancer screening test. The headline growth is offset by cash consumption. Preliminary free cash flow was approximately negative $54 million in Q4 2025 and negative $233 million for the full year, compared with negative $275 million in 2024, so cash burn improved year over year despite the revenue ramp. Cash, cash equivalents, restricted cash, and marketable debt securities totaled approximately $1.3 billion at December 31, 2025, providing a substantial liquidity cushion. Investors should treat these figures with caution. The company explicitly states that its financial statements are not yet complete, that the numbers are preliminary and unaudited, and that the independent auditors may identify items that cause final results to differ materially. Audited fourth-quarter and full-year results are expected during the February 2026 earnings call, and that release will be the reliable basis for valuation.

Jan 12, 2026 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Nov 7, 2025)

On November 7, 2025, Guardant Health closed two concurrent capital raises that together bring in roughly $717 million in net proceeds. The first is a public offering of 3,833,332 common shares at $90.00 per share, including the full 499,999-share underwriter option. Net proceeds were about $327.2 million. The second is a private offering of $402.5 million of 0% convertible senior notes due May 15, 2033, including the full $52.5 million option. Net proceeds were about $390.0 million. The company says the proceeds will fund general corporate purposes, which may include repurchasing a portion of its 0% convertible senior notes due 2027. The convertible notes carry an initial conversion price of about $121.50 per share, a 35% premium to the $90.00 offering price. Holders can convert before February 15, 2033 only under specified conditions, including a share-price test and the company's call or certain corporate events. From February 15, 2033, conversion is unrestricted. Guardant may not call the notes before November 20, 2029, and any call requires the stock to trade above 130% of the conversion price. Settlement can be in cash, shares, or a mix, at the company's election. The indenture includes customary events of default, including a $100.0 million cross-acceleration threshold. For investors, the key trade-off is dilution and balance-sheet management. The equity raise adds about 3.8 million shares now, and the notes could add up to about 4.47 million more shares on conversion, though cash settlement would avoid that issuance. The 0% coupon keeps near-term interest cost low. The company is also using the new capital to address its 2027 notes, so the net effect on leverage depends on how much of those notes it actually repurchases. The filing does not state the company's share count or current cash position, so the dilution percentage and liquidity impact cannot be fully quantified from this document alone.

Nov 7, 2025 10-Q

Guardant Health, Inc. Quarterly Report for Q3 Ended Sep 30, 2025

Guardant Health, Inc. reported a significant increase in revenue for the third quarter and first nine months of 2025, driven by strong performance in its Oncology and Biopharma segments. Total revenue grew by 39% year-over-year for the quarter to $265.2 million and by 30% for the nine-month period to $700.8 million. Despite revenue growth, the company continues to incur net losses, reporting a net loss of $92.7 million for the third quarter and $287.8 million for the nine months ended September 30, 2025. The company's significant investments in research and development, coupled with increased sales and marketing expenses to support product launches like Shield, contribute to these ongoing losses. However, the company maintains a healthy liquidity position with $689.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025, suggesting sufficient runway for operations.

Oct 29, 2025 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Oct 29, 2025)

Guardant Health (GH) reported third quarter 2025 results for the period ended September 30, 2025, with total revenue of $265.2 million, up 39% year over year from $191.5 million. Growth was broad-based: Oncology revenue rose 31% to $184.4 million on a 40% increase in test volume, Screening (Shield) contributed $24.1 million from roughly 24,000 tests versus $1.0 million a year earlier, and Biopharma & Data grew 18% to $54.7 million, partly driven by service-agreement milestone achievements. Non-GAAP gross margin expanded to 66% from 63%, and management noted the company crossed $1 billion in annualized revenue. Profitability improved meaningfully, though the company remains loss-making. GAAP net loss narrowed to $92.7 million from $107.8 million, and non-GAAP net loss improved to $48.3 million from $55.0 million. Adjusted EBITDA loss narrowed to $45.5 million from $56.2 million, and free cash flow burn was $(45.8) million versus $(55.3) million. Cash, cash equivalents and restricted cash totaled $689.5 million at quarter end. Non-GAAP operating expenses rose to $228.9 million from $187.3 million as the company invests in commercial expansion and the Shield launch. The key forward-looking development is a raised 2025 revenue guidance of $965 to $970 million, up from $915 to $925 million and implying about 31% growth. Screening guidance was lifted to $71 to $73 million on Shield volume of 80,000 to 82,000 tests, and the non-GAAP gross margin outlook was raised to 64% to 65%. Management raised non-GAAP operating expense guidance to $865 to $875 million to support the Shield launch, while free cash flow burn guidance of $225 to $235 million was maintained and is an improvement over 2024. The filing is a press-release furnishing under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

Oct 29, 2025 8-K

Guardant Health, Inc. 8-K Report, Regulation FD Disclosure (Sep 24, 2025)

Guardant Health, Inc. (GH) announced an upcoming Investor Day scheduled for September 24, 2025. This event will provide an opportunity for investors to hear directly from co-CEOs Helmy Eltoukhy and AmirAli Talasaz, along with other members of the executive management team. The presentations are expected to focus on the company's operational performance, strategic priorities, and updated financial outlook. This Investor Day presents a crucial opportunity for stakeholders to gain deeper insights into Guardant Health's current business trajectory and future plans. Investors should pay close attention to any new strategic initiatives, market expansion updates, and revisions to financial projections that may be shared during the event, as these could significantly impact the company's valuation and stock performance.

Sep 24, 2025 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Sep 15, 2025)

Guardant Health (GH) filed an 8-K on September 15, 2025 disclosing the appointment of Alex M. Azar II, former U.S. Secretary of Health and Human Services (2018–2021), to its Board of Directors. The Board increased its size from 10 to 11 members and named Azar a Class III director effective September 12, 2025, with a term expiring at the 2027 Annual Meeting. He was also placed on the Nominating and Corporate Governance Committee. The event is governance-focused and carries no disclosed financial impact. Azar's compensation follows the standard Amended Non-Employee Director Compensation Program: a stock option award and a restricted stock unit award, each valued at $362,500. Both vest in installments, with one-quarter vesting on the first anniversary of appointment and the remainder vesting monthly over the following three years, subject to continued service. He is also entering the Company's standard indemnification agreement. The filing reports no arrangements or related-party transactions requiring disclosure under Item 404(a). For investors, the appointment signals an effort to strengthen the Board's policy, government relations, and healthcare access expertise, which management tied to reimbursement, regulatory, and patient-access priorities. The filing itself does not quantify any operational or financial benefit, so the significance will depend on how the Company leverages his experience over time.

Sep 15, 2025 10-Q

Guardant Health, Inc. Quarterly Report for Q2 Ended Jun 30, 2025

Guardant Health, Inc. reported a significant increase in revenue for the second quarter and first half of 2025, driven by strong performance in its Oncology and Biopharma and Data segments. Total revenue for the three months ended June 30, 2025, was $232.1 million, up 31% year-over-year, and for the six months ended June 30, 2025, revenue reached $435.6 million, a 26% increase. The company also saw initial revenue from its newly launched Shield screening test. Despite revenue growth, Guardant Health continued to incur net losses, with a loss of $99.9 million for the quarter and $195.1 million for the first half of the year. The company's cash position remains robust with $735.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025, providing ample liquidity for over 12 months. Key developments include the expanding commercial reach of the Shield test, which received National Comprehensive Cancer Network guideline inclusion and met Medicare coverage requirements, alongside continued investment in research and development. The company also successfully managed its debt structure by completing a note exchange transaction in February 2025, which retired a portion of its 2027 notes and resulted in a gain on extinguishment. Management anticipates continued investment in sales and marketing to drive adoption and expansion, particularly with the Shield product line and international growth initiatives.

Jul 30, 2025 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Jul 30, 2025)

Guardant Health (GH) reported strong second quarter 2025 results, with total revenue of $232.1 million, up 31% year over year. Growth was broad-based: Oncology revenue rose 22% to $158.7 million on 30% test volume growth, Biopharma & Data revenue grew 28% to $56.0 million, and Shield screening contributed $14.8 million from roughly 16,000 tests. Non-GAAP gross margin expanded to 66% from 60%, and non-GAAP net loss narrowed to $55.0 million ($0.44 per share) from $58.5 million. Adjusted EBITDA loss improved to $51.9 million from $61.9 million, and free cash flow improved to $(65.9) million from $(99.1) million, though the year-over-year improvement was partly driven by timing of annual bonus payouts. Management raised 2025 revenue guidance to $915-$925 million (24%-25% growth), up from $880-$890 million. Screening revenue guidance rose to $55-$60 million on 68,000-73,000 Shield tests, and Oncology growth is now expected near 20%. Non-GAAP operating expenses guidance increased to $840-$850 million, reflecting reinvestment of incremental Screening gross profit into the Shield commercial build-out. Management continues to expect full-year free cash flow burn of $225-$235 million, including roughly $200 million of Screening cash burn, and expects the non-Screening business to reach free cash flow breakeven in Q4 2025. Key watch items for investors are the continued cash burn tied to Shield, the GAAP net loss of $99.9 million for the quarter, and the sustainability of Oncology reimbursement gains. Cash, cash equivalents and restricted cash totaled $735.5 million at June 30, 2025, while convertible senior notes principal had declined to $1.09 billion. Stockholders' deficit widened to $(305.5) million, and the company has not yet reached GAAP profitability.

Jul 30, 2025 8-K

Guardant Health, Inc. 8-K Report, Shareholder Vote Results (Jun 20, 2025)

Guardant Health, Inc. (GH) held its annual meeting of stockholders on June 18, 2025. The primary outcomes reported in this 8-K filing pertain to the election of directors, ratification of the independent auditor, and advisory approval of executive compensation. All director nominees presented in the proxy statement were elected, indicating strong shareholder confidence in the current board's composition and strategy. Additionally, shareholders overwhelmingly ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, a standard but important procedural approval for financial oversight. Furthermore, a non-binding advisory vote on the compensation of the company's named executive officers received majority approval. While the overall outcomes reflect shareholder support, investors should note the breakdown of votes for director nominee Musa Tariq, which showed a higher percentage of 'votes withheld' compared to other nominees. This is a point for potential further scrutiny or understanding of specific shareholder concerns. The strong ratification of the auditor and executive compensation proposals generally signal a stable governance environment.

Jun 20, 2025 10-Q

Guardant Health, Inc. Quarterly Report for Q1 Ended Mar 31, 2025

Guardant Health, Inc. reported a notable increase in revenue for the first quarter of 2025, up 21% year-over-year to $203.5 million. This growth was primarily driven by strong performance in its Oncology and Biopharma and data segments, reflecting increased test volumes and improved reimbursement for key tests like Guardant360 CDx and Guardant Reveal. The company also saw the initial revenue contribution from its Shield screening test, a positive development for its early cancer detection strategy. Despite the revenue growth, the company continued to incur significant operating losses, with a net loss of $95.2 million for the quarter. This was partly due to increased investments in research and development and a substantial rise in sales and marketing expenses, particularly related to expanding its commercial team and supporting new product launches like Shield. The company's cash position remains strong at over $800 million, providing runway for continued investment. Investors will be closely watching the company's progress in commercializing its screening tests and managing its expenses to achieve profitability.

Apr 30, 2025 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Apr 30, 2025)

Guardant Health (GH) reported first quarter 2025 results on April 30, 2025, with total revenue of $203.5 million, up 21% year over year from $168.5 million. Growth was broad-based: oncology revenue rose 20% to $150.6 million on 25% oncology test volume growth, biopharma & data revenue grew 21% to $45.4 million, and Shield screening contributed $5.7 million from roughly 9,000 tests. Gross margin improved to 63% GAAP (65% non-GAAP) from 61% (63%), and management said Shield and Reveal both reached positive gross margins in the quarter, driven by lower testing costs. Profitability remained negative but improved on a GAAP basis. GAAP net loss narrowed to $95.2 million ($0.77 per share) from $115.0 million ($0.94 per share), aided by a $13.7 million gain on extinguishment of convertible notes and a $7.9 million other income line. Non-GAAP net loss was $61.1 million ($0.49 per share) versus $56.4 million a year earlier, and adjusted EBITDA loss improved slightly to $58.5 million from $61.1 million. Operating expenses rose to $239.8 million GAAP, driven by commercial expansion and the Shield launch. Free cash flow was negative $67.1 million, worse than the prior year's $37.2 million, mainly due to timing of annual bonus payments. Cash, cash equivalents and restricted cash totaled $803.9 million at quarter end, and convertible notes principal fell to $1.09 billion from $1.15 billion. The company raised 2025 revenue guidance to $880-890 million (19-20% growth), up from $850-860 million, with screening revenue guidance lifted to $40-45 million on 52,000-58,000 Shield tests. Non-GAAP operating expense guidance rose to $830-840 million to fund accelerated Shield commercial buildout, and full-year free cash flow burn is expected at $225-235 million, including about $200 million of screening cash burn. Management expects the non-screening business to reach free cash flow breakeven in Q4 2025. The 8-K is a routine Item 2.02 furnishing of the earnings release; the information is furnished, not filed.

Apr 30, 2025 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Apr 9, 2025)

Guardant Health, Inc. has filed a Form 8-K to report on a material definitive agreement, specifically the third amendment to its existing lease for its Redwood City, California facilities. This amendment extends the lease term for various buildings within the facility to either December 31, 2030, or December 31, 2031. This extension comes with a commitment of approximately $50 million over the extended period, with base rent set to increase by 3% annually starting in 2026.

Apr 9, 2025 10-K

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2024

Guardant Health, Inc. (GH) presented its 2024 Annual Report on Form 10-K, highlighting significant revenue growth driven by its precision oncology testing business, which increased by 34% year-over-year to $687.9 million. This growth was fueled by a 34% rise in clinical testing revenue, attributed to increased sample volumes and improved reimbursement rates, particularly from Medicare for its Guardant360 LDT test. Biopharmaceutical revenue also saw a 31% increase. Despite top-line growth, the company continues to incur substantial net losses, with the 2024 net loss at $436.4 million, a slight improvement from $479.4 million in 2023. The company ended the year with a strong liquidity position, holding $944.2 million in cash, cash equivalents, restricted cash, and marketable debt securities, providing ample runway for continued investment in research and development, clinical studies, and commercial expansion. The company achieved a major milestone with the FDA approval and subsequent commercial launch of its Shield blood test for colorectal cancer screening in August 2024, making it the first FDA-approved blood test for primary colorectal cancer screening that also meets Medicare coverage requirements. This positions Guardant Health to address the critical early cancer detection market. Looking ahead, Guardant Health remains focused on expanding clinical utility, securing broader payer coverage and reimbursement, and growing its global commercial footprint. However, investors should remain aware of the significant risks outlined, including the ongoing unprofitability, dependence on reimbursement decisions, competitive pressures, and potential regulatory changes, particularly concerning Laboratory Developed Tests (LDTs).

Feb 20, 2025 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Feb 20, 2025)

Guardant Health (GH) reported Q4 and full-year 2024 results on February 20, 2025, with total revenue of $739.0 million for FY2024, up 31% year over year, and Q4 revenue of $201.8 million, up 30%. Precision oncology revenue grew 34% for the year to $687.9 million, though management disclosed an approximately $22 million non-recurring, out-of-period revenue benefit from better-than-expected cash collections on prior-year claims, which flatters the growth rate. Clinical oncology volume grew 20% for the year, and biopharma test volume grew 35%. Shield, the company's blood-based colorectal cancer screening test, began contributing revenue after FDA approval, generating $5.1 million in 2024 and roughly 6,400 screening tests in Q4 alone. Profitability improved mainly because 2023 included an $83.4 million non-recurring legal accrual. GAAP net loss narrowed to $436.4 million ($3.56 per share) from $479.4 million, and non-GAAP net loss improved to $247.2 million from $352.3 million. Free cash flow burn narrowed to $274.9 million from $345.5 million. Balance sheet activity was significant: in February 2025 the company exchanged $659.3 million of its 0% 2027 convertible notes for $600.0 million of new 1.25% notes due 2031, and repurchased $45.0 million of stock at $46.09 per share. Pro forma cash and marketable securities would be about $886.8 million, against $490.7 million of remaining 2027 notes. For 2025, management guided to total revenue of $850-860 million (15-16% growth, or 19-20% excluding the 2024 non-recurring item), screening revenue of $25-30 million on 45,000-50,000 Shield tests, non-GAAP gross margin of 62-63%, non-GAAP operating expenses of $815-825 million, and free cash flow burn of $225-235 million, including about $200 million of screening cash burn. Management expects the non-screening business to reach free cash flow breakeven in Q4 2025.

Feb 20, 2025 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Feb 14, 2025)

Guardant Health, Inc. (GH) announced a significant debt restructuring through privately negotiated exchange agreements, resulting in the issuance of $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (New Notes). These New Notes were exchanged for approximately $659.3 million principal amount of its outstanding 0% Convertible Senior Notes due 2027. This transaction effectively reduced the principal amount of outstanding convertible debt by approximately $59.3 million while extending the maturity profile of a portion of its debt to 2031 and introducing a modest interest cost. Investors should note that the company has strategically extended its debt maturity and reduced its near-term debt principal. The New Notes carry a 1.25% annual interest rate and are convertible into Guardant Health common stock at an initial conversion price of approximately $62.22 per share, representing a conversion premium of about 35% to the stock price on February 6, 2025. This convertible note structure allows the company to potentially issue shares at a premium, which could mitigate dilution compared to a cash repayment, while also providing flexibility for future capital management.

Feb 14, 2025 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Feb 7, 2025)

On February 6, 2025, Guardant Health entered into privately negotiated exchange agreements with certain holders of its 0% Convertible Senior Notes due 2027. The company will issue $600 million of new 1.25% Convertible Senior Notes due 2031 in exchange for retiring about $659.3 million of the 2027 Notes, which leaves roughly $490.7 million of the 2027 Notes outstanding on unchanged terms. The transaction is expected to close on or about February 14, 2025. Alongside the exchange, Guardant plans to repurchase about $80 million of its common stock in total: about $45 million from the company directly and about $35 million through the exchange agent, both at the February 6, 2025 last reported sale price. The company is effectively extending its debt maturity from 2027 to 2031 and cutting the principal outstanding by about $59 million, while adding a new coupon of 1.25%. The main investor takeaways are the lower leverage and the cost trade-off. The company's cash interest expense rises by about $7.5 million per year on the new notes, since the retired 2027 Notes carried no coupon. In exchange, Guardant gets about four additional years before the 2027 maturity wall and a conversion price of about $62.22, which is roughly a 35% premium to the February 6, 2025 reference price (implying a reference price of about $46.09). The initial conversion rate implies about 9.6 million shares on the $600 million of new notes, rising to a maximum of about 13.0 million shares under the maximum conversion rate after anti-dilution adjustments. Those shares would be issued under the Section 3(a)(9) exemption. The new notes have investor protections that matter for valuation and risk. Holders cannot convert before November 15, 2030 except upon specified events. The company cannot call the notes before February 21, 2028, and can then redeem them only if the stock trades above 130% of the conversion price (about $80.89) for a specified period. Calling a note triggers a make-whole conversion rate increase. Events of default include cross-acceleration on at least $100 million of debt. Investors should weigh the reduced refinancing risk against the modest increase in cash interest, the dilution potential from the conversion shares, and the partly offsetting effect of the stock repurchases.

Feb 7, 2025 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Jan 13, 2025)

Guardant Health (GH) filed an 8-K on January 13, 2025 furnishing preliminary, unaudited results for Q4 and full year 2024 ahead of the J.P. Morgan Healthcare Conference. Full-year 2024 revenue was approximately $737 million, up 31% year over year, driven by clinical and biopharma test volume growth and rising Guardant360 average selling prices (ASPs). Oncology clinical tests (excluding Shield) rose about 20% to roughly 206,700, and biopharma tests rose about 35% to roughly 40,500. Q4 revenue was approximately $200 million, up 29%, and the company reported about 6,400 Shield screening tests generating roughly $4 million of revenue in the first full quarter of Shield's commercial launch. The key concern for investors is cash burn. Preliminary free cash flow was approximately negative $275 million for full-year 2024 (versus negative $345 million in 2023) and approximately negative $84 million in Q4. Cash, cash equivalents, restricted cash and marketable debt securities totaled $944 million at December 31, 2024. In Q4, the company received $34 million from the sale of part of its Lunit investment, which is recorded in investing activities, and sold no shares under its at-the-market (ATM) program with Jefferies. The figures are explicitly preliminary and subject to change during year-end close and auditor review, and the company has not yet completed its financial statements. Audited results are expected during the February 2025 earnings call. The company is also scaling commercial infrastructure for Shield, which will likely require continued investment.

Jan 13, 2025 10-Q

Guardant Health, Inc. Quarterly Report for Q3 Ended Sep 30, 2024

Guardant Health, Inc. reported its third-quarter 2024 financial results, showcasing robust revenue growth driven by its precision oncology testing segment. Total revenue increased by 34% year-over-year to $191.5 million, with precision oncology testing revenue growing by 35% to $180.6 million. This growth was fueled by both increased test volumes from clinical customers and biopharmaceutical clients, along with improved reimbursement rates, particularly for the Guardant360 LDT test. Despite strong top-line performance, the company continues to operate at a net loss, reporting a loss of $107.8 million for the quarter. The company maintains a healthy liquidity position with approximately $1.0 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2024, providing runway for continued investment in research and development and commercial expansion. A significant development during the quarter was the achievement of performance metrics for certain performance-based restricted stock units (PSUs), leading to a cumulative charge of $23.5 million in stock-based compensation expense. While R&D expenses saw a slight decrease year-over-year, sales and marketing expenses increased significantly due to commercial team build-out and marketing efforts for product launches, including the Shield test. The company also noted progress in its intellectual property disputes and continues to advance its product pipeline and international expansion efforts.

Nov 6, 2024 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Nov 6, 2024)

Guardant Health reported third quarter 2024 revenue of $191.5 million, up 34% year over year from $143.0 million, driven by clinical test volume growth of 21% (excluding Shield), biopharma test volume growth of 40%, and higher Guardant360 reimbursement, including Medicare pricing of $5,000 effective January 1, 2024. Precision oncology revenue rose 35% to $180.6 million. GAAP gross margin was 61% and non-GAAP gross margin excluding screening costs was 65%. GAAP net loss widened to $107.8 million from $86.1 million, largely because of an $18.3 million increase in unrealized and realized losses on the company's Lunit investment. Non-GAAP net loss improved to $55.0 million from $79.2 million, and adjusted EBITDA loss narrowed to $56.2 million from $79.7 million. Management raised full-year 2024 revenue guidance to $720 to $725 million, representing 28% to 29% growth, from the prior range of $690 to $700 million. This is the third guidance increase of the year. Free cash flow guidance was revised to a $(265) to $(275) million outflow, an improvement of $70 to $80 million versus 2023. Non-GAAP operating expense guidance of $720 to $730 million and the 61% to 63% non-GAAP gross margin excluding screening outlook were unchanged. The quarter also marked the commercial launch of Shield IVD following FDA approval, with a Medicare price of $920 effective August 1, 2024. Cash, cash equivalents, restricted cash and marketable debt securities totaled $1.0 billion at quarter end. Investors should weigh the strong top-line momentum and improving cash burn against continued GAAP losses, high sales and marketing spend, and the volatility introduced by equity investment marks.

Nov 6, 2024 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Oct 24, 2024)

Guardant Health (Nasdaq: GH) filed an 8-K on October 24, 2024 to report a board change rather than a financial or operational event. Effective October 21, 2024, the Board increased its size to ten directors and appointed Roberto A. Mignone as a Class I director, with a term expiring at the 2025 Annual Meeting. He was also placed on the Audit Committee. Mignone is the Founder and Managing Partner of Bridger Management LLC, a long-term equity investment firm with a healthcare focus, and he previously co-founded Blue Ridge Capital LLC. The filing contains no financial results, guidance, or disclosed transaction amounts beyond standard director compensation. Mignone receives the Company's standard non-employee director package under its Amended Non-Employee Director Compensation Program: a stock option award and an RSU award, each valued at $362,500. Both vest over roughly three years, with 25% vesting on the first anniversary of his appointment and the remainder vesting monthly thereafter. He is also entering the Company's standard indemnification agreement. The filing states there are no arrangements under which he was selected and no related-party transactions reportable under Item 404(a). For investors, the main significance is governance. Adding a healthcare-focused investor with long-term equity experience to the Audit Committee may signal shareholder engagement and oversight, and the press release links the appointment to strengthening product offerings across the care continuum following the FDA approval of Shield for early-stage colorectal cancer screening. The filing itself does not link the appointment to any specific strategic or financial outcome.

Oct 24, 2024 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Aug 23, 2024)

Guardant Health, Inc. (GH) has entered into an Open Market Sale Agreement with Jefferies LLC, establishing an at-the-market (ATM) offering program. This agreement allows the company to sell up to $400.0 million of its common stock from time to time, at its discretion, through Jefferies acting as the sales agent. The offering will be conducted under the company's existing shelf registration statement on Form S-3, filed on May 22, 2023, with a prospectus supplement filed concurrently with this report. This strategic move provides Guardant Health with flexibility to raise capital as needed to support its ongoing operations, growth initiatives, or strategic opportunities without needing to file a new registration statement immediately.

Aug 23, 2024 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Aug 7, 2024)

Guardant Health (Nasdaq: GH) reported second quarter 2024 results on August 7, 2024, with total revenue of $177.2 million, up 29% year over year from $137.2 million. Precision oncology revenue grew 33% to $166.5 million, driven by clinical test volume growth of 14% and biopharma test volume growth of 56%, plus higher Medicare reimbursement for Guardant360 LDT ($5,000, effective January 1, 2024) and improved Medicare Advantage and commercial payer rates. Development services revenue declined to $10.7 million from $11.9 million. GAAP gross margin was 59% versus 61% a year earlier, and non-GAAP gross margin was 60% versus 62%, with development services margin compressing sharply to 37% from 62%. GAAP net loss widened to $102.6 million ($0.84 per share) from $72.8 million ($0.67 per share), primarily because of a $79.5 million year-over-year increase in unrealized losses on the company's equity security investment, which offset a prior-year $23.6 million impairment and a $19.0 million improvement in operating loss. Non-GAAP net loss narrowed to $58.5 million ($0.48 per share) from $88.7 million ($0.82 per share). Adjusted EBITDA loss improved to $61.9 million from $85.2 million, and free cash flow was $(99.1) million versus $(100.5) million, with $1.0 billion in cash, cash equivalents and restricted cash at June 30, 2024. Management raised full-year 2024 revenue guidance excluding screening to $690-$700 million (22%-24% growth) from $675-$685 million, while reaffirming non-GAAP gross margin excluding screening of 61%-63%, non-GAAP operating expenses of $720-$730 million, and free cash flow of $(275)-$(285) million. The quarter also included FDA approval of Shield as a first-line colorectal cancer screening option, the commercial launch of Shield IVD, and Medicare coverage covering roughly 45 million eligible individuals.

Aug 7, 2024 10-Q

Guardant Health, Inc. Quarterly Report for Q2 Ended Jun 30, 2024

Guardant Health, Inc. reported a significant increase in total revenue for the second quarter and first half of 2024, driven primarily by its Precision Oncology Testing segment. Total revenue for the three months ended June 30, 2024, rose by 29% year-over-year to $177.2 million, and for the six months ended June 30, 2024, revenue grew by 30% to $345.7 million. Despite revenue growth, the company continued to incur substantial net losses, with a loss of $102.6 million for the quarter and $217.6 million for the first half of the year. This is a key area for investors to monitor, as is the company's substantial cash balance of $1.0 billion as of June 30, 2024, which provides a sufficient runway for more than 12 months. A significant development during the period was the FDA approval and subsequent commercial launch of the Shield blood test for colorectal cancer screening in August 2024, positioning Guardant Health as a leader in early cancer detection.

Aug 7, 2024 8-K

Guardant Health, Inc. 8-K Report, Corporate Update (Jul 29, 2024)

Guardant Health (Nasdaq: GH) disclosed in an 8-K filed July 29, 2024 that the FDA approved its Shield blood test as a primary screening option for colorectal cancer (CRC) in adults aged 45 and older who are at average risk. Shield is described as the first blood-based CRC screening test approved by the FDA as a primary screening option and the first to meet performance requirements for Medicare coverage under NCD 210.3. The approval followed a strong recommendation from an FDA Advisory Committee panel in May 2024 and is supported by the 20,000+ patient ECLIPSE registrational study, which reported 83% CRC sensitivity and 90% specificity for advanced neoplasia. For investors, the key implication is a potential expansion of Guardant's addressable screening market. The company states that Shield's real-world adherence rate has exceeded 90% since its May 2022 LDT launch, compared with 28-71% for colonoscopy and stool-based tests, and that the test is expected to be covered for eligible Medicare beneficiaries. Management said it is preparing to launch the test in the near future. Commercial coverage is expected to broaden further once the American Cancer Society and the U.S. Preventive Services Task Force include Shield in their guidelines, which is anticipated but not yet done. The filing is primarily a press release disclosure under Item 8.01 (Other Events). It contains no financial results, guidance, or quantitative commercial targets. Investors should weigh the regulatory milestone against the uncertainties the filing itself flags: the timing of the commercial launch, the pace of Medicare and commercial reimbursement, the pending guideline inclusion, and the forward-looking statement risks tied to the company's 10-K for fiscal 2023.

Jul 29, 2024 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Jul 18, 2024)

Guardant Health (Nasdaq: GH) filed an 8-K on July 18, 2024 to disclose the appointment of Dr. Manuel Hidalgo Medina to its Board of Directors. The Board increased its size from eight to nine members on July 17, 2024, and appointed Dr. Hidalgo as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. He was also placed on the Nominating and Corporate Governance Committee. The filing is a governance event rather than a financial disclosure, and it includes no reported financial results, guidance, or material operational changes. Dr. Hidalgo is Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and he is the Walter B. Wriston Professor of Pancreatic Cancer Research. He has more than 20 years of experience in translational and clinical anticancer drug development, with a focus on gastrointestinal cancers and early clinical development for pancreatic cancer. He previously led hematology at Beth Israel Deaconess Medical Center and served as Clinical Director of the Rosenberg Clinical Cancer Center from 2015 to 2019. He also sits on the board of Bristol-Myers Squibb. For Guardant, his oncology expertise adds clinical and drug-development perspective to the board, which is relevant to a company whose tests span screening, recurrence monitoring, and treatment selection. His compensation follows the standard non-employee director program. He receives a stock option award and a restricted stock unit award, each valued at $362,500, vesting over roughly three years, with one-quarter vesting at the first anniversary and the remainder vesting monthly thereafter. The Company is also entering into its standard indemnification agreement with him. The filing reports no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K, and no arrangements with other persons under which he was selected. Investors should view this as a routine board refresh with limited direct financial impact.

Jul 18, 2024 8-K

Guardant Health, Inc. 8-K Report, Shareholder Vote Results (Jun 14, 2024)

Guardant Health, Inc. (GH) reported the results of its 2024 Annual Meeting of Stockholders held on June 12, 2024. The meeting saw the election of all director nominees, indicating strong shareholder confidence in the current board's leadership and strategic direction. Furthermore, shareholders ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, which is a standard procedural approval. However, a notable outcome was the advisory vote on executive compensation; the proposal to approve the compensation of named executive officers did not pass on a non-binding basis. This suggests some shareholder concerns or dissatisfaction regarding executive pay, which the company will need to address.

Jun 14, 2024 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (May 31, 2024)

Guardant Health, Inc. (GH) filed an 8-K on May 31, 2024, detailing amendments to its Executive Severance Plan. These changes, effective May 24, 2024, primarily impact the severance packages for executive employees, particularly in scenarios involving termination without cause or for good reason, and in connection with a change in control. The amendments standardize severance benefits, with increased payouts and accelerated equity vesting for Co-CEOs Helmy Eltoukhy and AmirAli Talasaz, especially during a change in control event. The revised plan provides for enhanced severance benefits, including extended salary and COBRA payments, and accelerated vesting of equity awards. Notably, these enhanced benefits are more generous for Co-CEOs, with provisions for 18 to 24 months of salary and COBRA payments, and full or significantly accelerated vesting of their equity awards under specific termination conditions and change in control scenarios. These updates reflect a strategic review and aim to align executive compensation and retention with potential future corporate events.

May 31, 2024 8-K

Guardant Health, Inc. 8-K Report, Corporate Update (May 24, 2024)

On May 23, 2024, Guardant Health (Nasdaq: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee strongly recommended approval of its Shield blood test for colorectal cancer (CRC) screening in adults aged 45 and older who are at average risk. The panel voted 8-1 that Shield is reasonably safe, 6-3 that it is reasonably effective, and 7-2 that its benefits outweigh its risks. The recommendation is non-binding, and the FDA will weigh it alongside other factors in its ongoing premarket approval (PMA) review, with a decision expected later in 2024. The committee's support rests on the pivotal ECLIPSE study, published in the March 2024 New England Journal of Medicine, which reported 83% sensitivity for CRC and 90% specificity for advanced neoplasia. Management notes that the sensitivity is within the 67%-92% range of existing stool-based primary screening tests. The company positions Shield as a blood-draw alternative for patients who are deterred by stool-based testing, and states that the test is on track to become the first FDA-approved blood test meeting Medicare coverage performance requirements under NCD 210.3. For investors, the key takeaway is that a favorable panel vote materially de-risks the Shield approval pathway and supports the commercial thesis for the company's screening franchise. However, this is an advisory opinion rather than an approval, and the filing does not disclose the FDA's timing with certainty, the commercial or reimbursement impact, or revenue expectations. The 6-3 effectiveness vote, the narrowest of the three, is a point worth monitoring in the final FDA decision.

May 24, 2024 10-Q

Guardant Health, Inc. Quarterly Report for Q1 Ended Mar 31, 2024

Guardant Health, Inc. reported a 31% increase in total revenue for the first quarter of 2024, reaching $168.5 million, driven primarily by a 38% surge in precision oncology testing revenue to $156.2 million. This growth was fueled by higher test volumes and improved reimbursement rates, particularly for their Guardant360 LDT and CDx tests. Despite the top-line growth, the company continued to operate at a significant net loss of $115.0 million, though this was an improvement from the $133.5 million loss in the prior year's quarter. The company's substantial cash reserves of $1.1 billion provide a strong liquidity position, enabling continued investment in research and development, including advancements in early cancer detection tests like Shield for colorectal and lung cancer.

May 9, 2024 8-K

Guardant Health, Inc. 8-K Report, Financial Results (May 9, 2024)

Guardant Health (GH) reported first quarter 2024 results on May 9, 2024, with total revenue of $168.5 million, up 31% year over year from $128.7 million. Precision oncology revenue grew 38% to $156.2 million, driven by clinical test volume growth of 20% (46,900 tests), biopharma test volume growth of 37% (8,450 tests), and higher reimbursement, including an increase in the Medicare rate for Guardant360 LDT to $5,000 effective January 1, 2024. GAAP gross margin improved to 61% from 59%, and non-GAAP gross margin excluding screening reached 64%. Operating performance improved meaningfully: GAAP loss from operations narrowed to $99.7 million from $134.1 million, and free cash flow improved to $(37.2) million from $(82.0) million. Management noted the first quarter of positive cash flow in the Therapy Selection business. The company raised its full-year 2024 revenue guidance (excluding screening) to $675-$685 million, implying 20-21% growth, up from $655-$670 million. It also improved its free cash flow outlook to $(275)-$(285) million from $(320)-$(330) million and lowered its non-GAAP operating expense guidance to $720-$730 million. Management highlighted an upcoming FDA Advisory Committee review of Shield IVD on May 23, 2024, with a product launch expected shortly after anticipated FDA approval in 2024. Net loss narrowed to $115.0 million ($0.94 per share) from $133.5 million ($1.30 per share), but the GAAP comparison was pressured by a $30.1 million unrealized loss on the company's marketable equity securities (investment in Lunit), partly offset by higher interest income. Non-GAAP net loss was $56.4 million ($0.46 per share). The company held $1.1 billion in cash, cash equivalents and restricted cash at March 31, 2024, against $1.14 billion in convertible senior notes, and total stockholders' equity fell to $68.3 million from $158.7 million.

May 9, 2024 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Mar 22, 2024)

Guardant Health, Inc. (GH) announced updates to the compensation arrangements for its Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024. The company has entered into new letter agreements that primarily adjust the incentive compensation structure, moving away from traditional salaries and cash bonuses towards equity awards. This move signals a continued focus on aligning executive compensation with long-term company performance and shareholder value creation. Key changes include maintaining a nominal base salary of $1 per year, with future salary adjustments to be determined by the Compensation Committee. Instead of salary and annual bonuses, each Co-CEO will receive annual grants of Restricted Stock Units (RSUs) and Performance-based RSUs (PSUs) valued at $800,000. Additionally, they will receive significant long-term awards of RSUs and PSUs valued at $5,000,000 each, tied to multi-year performance metrics. The cancellation of prior PSU awards is also noted. These adjustments underscore a strong emphasis on performance-driven incentives and long-term commitment from the leadership team.

Mar 22, 2024 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Feb 22, 2024)

Guardant Health (GH) reported Q4 and full-year 2023 results on February 22, 2024, with full-year revenue of $563.9 million, up 25% year over year, driven by clinical test volume growth of 39%. Precision oncology revenue grew 31% to $514.2 million, while development services and other revenue fell 14% to $49.7 million on lower companion diagnostic milestone timing and reduced royalties. Gross margin declined to 60% from 65%, mainly due to product mix and the cost of processing Shield LDT samples for which the company is booking minimal revenue. Free cash flow improved to negative $345.5 million from negative $386.9 million, and the company ended the year with $1.2 billion in cash, cash equivalents and marketable debt securities. GAAP results were distorted by an $83.4 million non-recurring legal accrual recorded in Q4 2023, which pushed the full-year GAAP net loss to $479.4 million (or $4.28 per share), versus $654.6 million in 2022. Excluding the accrual and other non-GAAP adjustments, non-GAAP net loss was $352.3 million, or $3.15 per share, compared with $4.26 per share in 2022. Adjusted EBITDA loss narrowed to $344.2 million from $403.4 million. Management noted that the Therapy Selection business reached cash flow breakeven by year-end 2023. Looking ahead, Guardant guided 2024 revenue (excluding screening) to $655–$670 million, implying 16%–19% growth, with non-GAAP gross margin excluding screening of 60%–62%, non-GAAP operating expenses of $740–$750 million, and free cash flow of negative $320–$330 million. The company is awaiting FDA approval of its Shield blood-based colorectal cancer screening test, with an Advisory Committee Panel expected as the next step; the Shield IVD launch is planned for later in 2024 following approval. Investors should watch the FDA review outcome, the Guardant360 LDT reimbursement increase from $3,500 to $5,000 effective January 1, 2024, and whether the legal accrual represents a one-time charge.

Feb 22, 2024 10-K

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2023

Guardant Health, Inc. reported a total revenue of $563.9 million for the year ended December 31, 2023, a 25% increase year-over-year, driven primarily by a 31% rise in precision oncology testing revenue. Despite this top-line growth, the company continued to incur significant net losses, amounting to $479.4 million for the year. The company has a substantial cash and cash equivalents balance of $1.1 billion as of December 31, 2023, which it believes is sufficient to fund its operations for more than 12 months. The company is focused on expanding its product portfolio and market adoption, particularly with its Shield test for early cancer detection, for which a PMA was submitted to the FDA. However, significant risks remain, including the company's ongoing unprofitability, dependence on third-party payer coverage and reimbursement, and intense competition in the precision oncology market. A recent jury verdict in a patent infringement case resulted in an $83.4 million liability accrual, which is a significant concern for investors.

Feb 22, 2024 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Feb 1, 2024)

Guardant Health, Inc. (GH) announced a change in its Board of Directors through an 8-K filing on February 1, 2024. Specifically, Mr. Samir Kaul has notified the Board of his intention to resign as a director and as a member of the compensation committee, effective February 1, 2024. This departure is stated to be amicable, with no disputes or disagreements cited as the reason for his resignation. Following Mr. Kaul's resignation, the size of the Board will be reduced from nine to eight directors. Investors should note that while this filing details a director's departure, it does not appear to be related to any operational or policy disagreements, suggesting a smooth transition. The reduction in board size is a minor structural adjustment and is not expected to have a significant immediate impact on the company's strategic direction or operational performance.

Feb 1, 2024 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Jan 8, 2024)

Guardant Health (GH) released preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, ahead of the J.P. Morgan Healthcare Conference. Full-year revenue is expected to be between $562 million and $563 million, up 25% year over year. Clinical test volume grew 39% to 172,900 tests, and biopharma test volume grew 15% to 29,900. Fourth-quarter revenue is expected to be between $153 million and $154 million, up 21%, with clinical tests up 29% to 46,400 and biopharma tests up 16% to 9,500. Profitability and cash burn remain the central investor concerns. Management said the therapy selection business reached breakeven, which it attributes to tailwinds during the year. Free cash flow was approximately negative $84 million in the fourth quarter and negative $347 million for the full year, compared with negative $387 million in 2022. The reconciliation shows full-year operating cash outflow of $328 million plus $19 million in capital expenditures. Cash, cash equivalents and marketable debt securities totaled $1.2 billion at year-end. The figures are not final. Guardant has not completed its year-end close, and its independent accountants may identify items that cause final results to differ materially. Audited results are due on the February 2024 earnings call. Management is focused on the anticipated launch of Shield IVD in 2024 following FDA approval, which it expects to be transformative for colorectal cancer screening.

Jan 8, 2024 8-K

Guardant Health, Inc. 8-K Report, Material Agreement (Dec 21, 2023)

On December 20, 2023, Guardant Health (Nasdaq: GH) agreed to sell 3,387,446 shares of common stock to institutional investors in a registered direct offering at $26.77 per share, for gross proceeds of approximately $90.7 million. The sale closed on December 21, 2023, with estimated net proceeds of about $90.6 million after offering expenses. Baillie Gifford, acting as agent and representative for the participating investors, led the transaction. The shares were issued under the company's automatic shelf registration on Form S-3 (File No. 333-272121), filed May 22, 2023. The company states it will use the proceeds primarily for general corporate purposes, including working capital, operating expenses and capital expenditures. The filing does not specify a particular project or acquisition, so the capital is best viewed as balance-sheet flexibility rather than a funded strategic initiative. Investors should also note that the issuance adds roughly 3.4 million shares to the outstanding count; the filing does not disclose the total share count, so the precise dilution percentage cannot be computed from this document alone. From an investor perspective, the event is a modest, primarily financing-driven update. The transaction was priced at a premium to typical market levels only if compared against the prevailing share price, which the filing does not report, and the endorsement by a large long-term institutional holder is the most notable qualitative element. Readers should review the company's latest 10-Q or 10-K for current cash, debt, and share count to assess the offering's significance relative to the balance sheet.

Dec 21, 2023 8-K

Guardant Health, Inc. 8-K Report, Corporate Update (Dec 19, 2023)

Guardant Health (Nasdaq: GH) filed an 8-K on December 19, 2023 to disclose that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval (PMA) application for its Shield blood test for colorectal cancer screening on March 28, 2024. The date is not final and remains subject to FDA confirmation and publication in the Federal Register. The company had submitted the final module of its PMA on March 10, 2023, supported by the ECLIPSE registrational study of more than 20,000 average-risk adults. For investors, the event is a meaningful regulatory milestone rather than a financial one. An advisory panel review is typically a precursor to a final FDA decision, and management stated that the proposed timing aligns with its expectation to complete the PMA process and launch Shield as an in-vitro diagnostic (IVD) in 2024. The filing contains no financial results, guidance changes, or quantitative disclosures on revenue or commercial impact. The key uncertainties are that the panel date could shift, the panel's vote and FDA's eventual decision are not guaranteed, and the filing does not address reimbursement, pricing, or expected market size for Shield. Investors should treat the announcement as a positive catalyst on the regulatory timeline while recognizing that approval outcomes and commercial adoption remain open questions.

Dec 19, 2023 8-K

Guardant Health, Inc. 8-K Report, Corporate Update (Nov 15, 2023)

On November 14, 2023, a federal jury in the U.S. District Court for the District of Delaware returned a verdict in favor of TwinStrand Biosciences and the University of Washington against Guardant Health in a patent infringement case. The jury found that Guardant willfully infringed U.S. Patent Nos. 10,287,631 and 10,760,127 and awarded plaintiffs $83.4 million, equal to a 6% royalty on past sales. The judgment is expected to be entered in the coming weeks, after which plaintiffs may seek to enhance damages up to three times given the willfulness finding. Guardant strongly disputes the verdict and plans to contest it through post-trial motions in the district court, including motions to overturn the verdict, seek a new trial, or amend the judgment, and then through appeal to the U.S. Court of Appeals for the Federal Circuit. The company states that it does not expect the verdict to materially affect its business. However, it cautions that if the verdict is upheld on appeal, the court may require royalty payments on future sales, which could increase future expenses. For investors, the immediate financial exposure is the $83.4 million award, with a potential enhancement of up to roughly $250 million if trebled, though the outcome remains subject to lengthy post-trial and appellate review. The filing also includes a press release in which management reiterates its confidence that Guardant did not infringe the asserted patents. The key uncertainties are the final judgment amount, the outcome of post-trial motions and appeal, and any ongoing royalty obligation on future sales.

Nov 15, 2023 10-Q

Guardant Health, Inc. Quarterly Report for Q3 Ended Sep 30, 2023

Guardant Health, Inc. (GH) reported strong revenue growth in its third-quarter and year-to-date filings for 2023, driven primarily by its Precision Oncology Testing segment. Total revenue increased by 22% year-over-year for the quarter to $143 million and by 27% year-to-date to $408.9 million. This growth was supported by increased test volumes in both clinical and biopharmaceutical customer segments. Despite revenue expansion, the company continued to incur significant net losses, with a Q3 net loss of $86.1 million and a year-to-date net loss of $292.4 million. However, the net loss narrowed considerably compared to the previous year, particularly for the nine-month period, indicating improved operational efficiency or cost management. The company strengthened its financial position, ending the period with $457.3 million in cash and cash equivalents and $697.5 million in short-term marketable debt securities, totaling over $1.15 billion in liquid assets. This robust liquidity is bolstered by a $381.4 million net proceeds from a follow-on public offering completed in May 2023, providing significant runway for continued investment in R&D and commercial expansion. Key developments include continued progress on the Shield test for early cancer detection, with an FDA PMA submission and positive results from the ECLIPSE study, positioning the company for potential future growth in the early detection market.

Nov 6, 2023 8-K

Guardant Health, Inc. 8-K Report, Financial Results (Nov 6, 2023)

Guardant Health (GH) reported third quarter 2023 results on November 6, 2023, with revenue of $143.0 million, up 22% year over year, driven by 35% growth in clinical test volume to 43,900 tests. Precision oncology revenue grew 31%, though development services and other revenue fell 37% on the timing of partnership milestones and lower royalties. The quarter also included a $3.6 million Medicare appeal payment covering 2018–2020 claims, which flatters the top line and should be viewed as non-recurring. Management raised full-year 2023 revenue guidance to $553–556 million (23%–24% growth), up from the prior range, and reiterated expectations for operating expenses below 2022 levels and free cash flow of approximately negative $350 million. Profitability improved meaningfully. GAAP net loss narrowed to $86.1 million ($0.73 per share) from $162.0 million a year earlier, helped by a $31.1 million improvement in operating loss and a $29.9 million swing in unrealized gains, which are non-operating and non-recurring in nature. Non-GAAP net loss was $79.2 million ($0.67 per share) versus $120.8 million, and Adjusted EBITDA loss narrowed to $79.7 million from $112.8 million. Gross margin compressed to 60% from 66%, primarily because development services margins fell sharply and product mix shifted, while precision oncology gross margin held near 60%. Liquidity remains substantial at $1.2 billion in cash, cash equivalents and marketable debt securities as of September 30, 2023, though quarterly free cash flow was negative $80.2 million and nine-month free cash flow was negative $262.7 million, so the company continues to consume cash. Operationally, management highlighted Medicare coverage uplifts for Guardant360 ASPs, first PEGASUS MRD de-escalation trial data at ESMO, and progress on the Shield blood-based colorectal cancer screening test. Investors should monitor whether the revenue acceleration and expense discipline can sustain the path toward reduced cash burn.

Nov 6, 2023 8-K

Guardant Health, Inc. 8-K Report, Executive Changes (Nov 3, 2023)

Guardant Health, Inc. (GH) announced the resignation of its Chief Operating Officer, Ms. Ines Dahne-Steuber, effective November 10, 2023. While she will be departing from her COO role, Ms. Dahne-Steuber will continue to be employed by the company until December 1, 2023, to ensure a smooth transition of her responsibilities. This development marks a significant change in the company's executive leadership team, and investors will be keen to understand the reasons behind the departure and the plan for succession. The company has not yet announced a replacement for the COO position. The transition period through December 1st suggests an orderly handover is being prioritized. Investors should monitor future filings and announcements for updates on the new COO appointment and any strategic implications this change may have on Guardant Health's operations and growth trajectory.

Nov 3, 2023 8-K

Guardant Health, Inc. 8-K Report, Regulation FD Disclosure (Sep 7, 2023)

Guardant Health, Inc. announced its upcoming Investor Day event scheduled for September 7, 2023. This event will feature presentations from co-CEOs Helmy Eltoukhy and AmirAli Talasaz, along with other executive management members. The primary focus will be on providing updates regarding the company's operations, key strategic priorities, and its financial outlook. Investors are encouraged to attend or access the live and archived webcast of the presentation through the "Investors" section of Guardant Health's website. This disclosure is made under Regulation FD, and while it provides important forward-looking information, it is furnished and not deemed "filed" under the Securities Exchange Act of 1934, meaning it does not carry the same liability as formally filed documents.

Sep 7, 2023